Guaiazulen

Guaiazulen

SCHEMBL29639620

Cc1ccc(C(C)C)cc2c(C)ccc1-2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 1.00
PTGS1 P23219 2/20 0.58
TRPA1 O75762 1/20 0.58
CACNA1C Q13936 1/20 0.58
HTT P42858 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.40
ALOX12 P18054 1/20 0.40
HIF1A Q16665 1/20 0.40
ACHE P22303 5/20 0.39
BCHE P06276 4/20 0.39
PTGS2 P35354 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RNASEH1 O60930 1/20 0.38
HPGD P15428 1/20 0.37
GFER P55789 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PDK2 Q15119 1/20 0.37
TYR P14679 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guaiazulen SCHEMBL26982 1.00 LMNA (1.00) LMNAPTGS1TRPA1CACNA1CHTT
Guaiazulen SCHEMBL29259925 1.00 LMNA (1.00) LMNAPTGS1TRPA1CACNA1CHTT
Guaiazulen SCHEMBL27806695 0.98 LMNA (0.95) LMNAPTGS1TRPA1CACNA1CHTT
Guaiazulen SCHEMBL7916824 0.98 LMNA (0.95) LMNAPTGS1TRPA1CACNA1CHTT
SCHEMBL31051327 0.95 LMNA (0.90) LMNAPTGS1TRPA1CACNA1CHTT
SCHEMBL10416092 0.93 LMNA (0.86) LMNAPTGS1TRPA1CACNA1CHTT
Guaiazulen SCHEMBL28588570 0.88 LMNA (0.77) LMNAPTGS1TRPA1CACNA1CACHE
SCHEMBL20676163 0.87 LMNA (0.77) LMNAPTGS1TRPA1CACNA1CHTT
Guaiazulen SCHEMBL28572432 0.86 LMNA (0.74) LMNAPTGS1TRPA1CACNA1CACHE
SCHEMBL12515665 0.81 LMNA (0.68) LMNAPTGS1TRPA1CACNA1CALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398702-B2 Method and system using small molecule absorbers to create a photothermal actuator THE REGENTS OF THE UNIVERSITY OF CALIFORNI (US) 2025-08-26 US claimed
CN-117534592-A Method for synthesizing 1, 4-dimethyl-7-isopropyl azulene-3-sodium sulfonate 许荧 2024-02-09 CN claimed
CN-117074572-A Method for detecting related substances of 1, 4-dimethyl-7-isopropyl azulene-3-sodium sulfonate and related preparations thereof 成都阿奇生物医药科技有限公司 2023-11-17 CN claimed
CN-116917295-A Metal complexes with 4-H, 6-H or 8-H-dihydroazulene ligands and uses thereof 优米科尔股份公司及两合公司 2023-10-20 CN claimed
US-20230332581-A1 METHOD AND SYSTEM USING SMALL MOLECULE ABSORBERS TO CREATE A PHOTOTHERMAL ACTUATOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-19 US claimed
EP-4047003-A1 METAL COMPLEXES WITH 4-H-, 6-H- OR 8-H-DIHYDROAZULENYL LIGANDS AND THEIR USE UMICORE AG & Co. KG (DE) 2022-08-24 EP claimed
US-12414977-B2 Method of administering seaberry and saw palmetto extracts to inhibit 5α-reductase activity ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) 2025-09-16 US disclosed
US-20250268972-A1 5a-REDUCTASE INHIBITOR ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) 2025-08-28 US disclosed
US-12398702-B2 Method and system using small molecule absorbers to create a photothermal actuator THE REGENTS OF THE UNIVERSITY OF CALIFORNI (US) 2025-08-26 US disclosed
US-12398702-B2 Method and system using small molecule absorbers to create a photothermal actuator THE REGENTS OF THE UNIVERSITY OF CALIFORNI (US) 2025-08-26 US disclosed
CN-114929340-B Methods and agents for glaucoma 奥夫博医疗创新有限公司 2025-06-10 CN disclosed
US-12221495-B2 Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide IGISU CO., LTD. (JP) 2025-02-11 US disclosed
CN-118806612-B Oil-in-oil microcapsule loaded with guaazulene and preparation method and application thereof 杭州岛屿星晴生物技术有限公司 2024-12-20 CN disclosed
WO-2022175112-A1 NOBLE METAL COMPLEXES WITH DIHYDROAZULENYL LIGANDS AND USE THEREOF UMICORE AG & CO. KG (DE) 2022-08-25 WO disclosed
EP-4047003-A1 METAL COMPLEXES WITH 4-H-, 6-H- OR 8-H-DIHYDROAZULENYL LIGANDS AND THEIR USE UMICORE AG & Co. KG (DE) 2022-08-24 EP disclosed
CN-114929340-A Methods and agents for glaucoma 奥夫博医疗创新有限公司 2022-08-19 CN disclosed
EP-4031244-A1 PROCESSES AND AGENTS FOR GLAUCOMA Aufbau Medical Innovations Limited (IE) 2022-07-27 EP disclosed
US-20220211800-A1 PROCESSES AND AGENTS FOR GLAUCOMA CORNELL UNIVERSITY (US) 2022-07-07 US disclosed
EP-4014987-A2 CYCLIC PEPTIDE, AND MEDICINE, EXTERNAL PREPARATION AND COSMETIC EACH CONTAINING SAID CYCLIC PEPTIDE Igisu Co., Ltd. (JP) 2022-06-22 EP disclosed
CN-114441571-A Method for determining molecular structure based on three-dimensional electron diffraction 苏州青云瑞晶生物科技有限公司 2022-05-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220211800-A1 PROCESSES AND AGENTS FOR GLAUCOMA RHOA, PDE6C, EXOSC10 LMNA 2151/4885PTGS1 110/4885TRPA1 1288/4885
US-12221495-B2 Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide TSLP, NPR1, VIP LMNA 4657/4885PTGS1 1115/4885TRPA1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.